Vivo is expected to hold a major launch event in April in China. The event is likely to see the arrival of multiple devices, ...

Vivo is gearing up to launch its next big flagship, the X200 Ultra. Expected to launch in China sometime between mid-to-late ...

STUNNING in Ancora Red and other eye-catching shades, the latest addition to vivo's V series has finally arrived in the Philippines: the V50. "Mobile phones nowadays have become so much more than just ...

The top end model of Asus ZenBook A14 with the Snapdragon X Elite chipset supports 90W fast charging, while the variant with Snapdragon X processor supports 65W fast charging. Both variants include a ...

In fact, even some high-end smartphones fail to impress us when it comes to photography. Vivo is one of the few smartphone brands that has been challenging this notion, and with its latest vivo V50, ...

Truist analyst Joon Lee lowered the firm’s price target on Intellia Therapeutics (NTLA) to $50 from $90 and keeps a Buy rating on the shares.

Intellia Therapeutics’ stock faces risks from market uncertainty and funding needs. Read why NTLA stock is downgraded to HOLD ...

If you've got any interest in skygazing, this is your week. A stunning planet parade is now visible in the night sky. A planet parade is when several of our solar system's planets are visible in ...

Intellia reports better-than-expected fourth-quarter 2024 results. The company provides updates on its pipeline candidates.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Intellia's technology platform specializes in Clustered Regularly Interspaced Short ...

John Leonard; President, Chief Executive Officer, Director; Intellia Therapeutics Inc David Lebwohl; Executive Vice President, Chief Medical Officer; Intellia Therapeutics Inc Edward Dulac; Executive ...